T Louie

Summary

Affiliation: University of Calgary
Country: Canada

Publications

  1. pmc How should we respond to the highly toxogenic NAP1/ribotype 027 strain of Clostridium difficile?
    Thomas J Louie
    Infectious Diseases Division, Department of Medicine, University of Calgary, Alta
    CMAJ 173:1049-50. 2005
  2. pmc Clostridium difficile infection in hospitals: risk factors and responses
    Thomas J Louie
    Department of Medicine, University of Calgary
    CMAJ 171:45-6. 2004
  3. ncbi request reprint Understanding influenza vaccination attitudes at a Canadian cancer center
    Manuel W Mah
    Infection Prevention and Control Program, Calgary Health Region, The University of Calgary, Canada
    Am J Infect Control 33:243-50. 2005
  4. ncbi request reprint Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea
    Thomas J Louie
    University of Calgary, Calgary, Alberta, Canada
    Clin Infect Dis 43:411-20. 2006
  5. pmc Development of a Health-Related Quality of Life Questionnaire (HRQL) for patients with Extremity Soft Tissue Infections (ESTI)
    Aric J Storck
    Department of Emergency Medicine, Calgary Health Region, Calgary, Alberta, Canada
    BMC Infect Dis 6:148. 2006
  6. pmc Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection
    T Louie
    University of Calgary, Calgary, Alberta, Canada
    Antimicrob Agents Chemother 53:223-8. 2009
  7. doi request reprint Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease
    B Guo
    Institute of Health Economics, Edmonton, Alberta, Canada
    Aliment Pharmacol Ther 35:865-75. 2012
  8. pmc Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada
    Duncan R MacCannell
    Department of Microbiology and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada
    J Clin Microbiol 44:2147-52. 2006
  9. ncbi request reprint Treatment of first recurrences of Clostridium difficile-associated disease: waiting for new treatment options
    Thomas J Louie
    Clin Infect Dis 42:765-7. 2006
  10. ncbi request reprint Population-based epidemiological study of infections caused by carbapenem-resistant Pseudomonas aeruginosa in the Calgary Health Region: importance of metallo-beta-lactamase (MBL)-producing strains
    Kevin B Laupland
    Department of Medicine, University of Calgary, Centre for Anti microbial Resistance, and Calgary Health Region, Calgary, Alberta, Canada
    J Infect Dis 192:1606-12. 2005

Collaborators

Detail Information

Publications12

  1. pmc How should we respond to the highly toxogenic NAP1/ribotype 027 strain of Clostridium difficile?
    Thomas J Louie
    Infectious Diseases Division, Department of Medicine, University of Calgary, Alta
    CMAJ 173:1049-50. 2005
  2. pmc Clostridium difficile infection in hospitals: risk factors and responses
    Thomas J Louie
    Department of Medicine, University of Calgary
    CMAJ 171:45-6. 2004
  3. ncbi request reprint Understanding influenza vaccination attitudes at a Canadian cancer center
    Manuel W Mah
    Infection Prevention and Control Program, Calgary Health Region, The University of Calgary, Canada
    Am J Infect Control 33:243-50. 2005
    ..Understanding health care worker perceptions and needs is essential for improving rates of vaccination...
  4. ncbi request reprint Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea
    Thomas J Louie
    University of Calgary, Calgary, Alberta, Canada
    Clin Infect Dis 43:411-20. 2006
    ..difficile-associated diarrhea, and selection for nosocomial pathogens. Tolevamer, a soluble, high-molecular weight, anionic polymer that binds C. difficile toxins A and B is a unique nonantibiotic treatment option...
  5. pmc Development of a Health-Related Quality of Life Questionnaire (HRQL) for patients with Extremity Soft Tissue Infections (ESTI)
    Aric J Storck
    Department of Emergency Medicine, Calgary Health Region, Calgary, Alberta, Canada
    BMC Infect Dis 6:148. 2006
    ..The objective of this study was to develop a health-related quality of life questionnaire (HRQL) for patients with extremity soft tissue infections (ESTI) for future use in clinical trials...
  6. pmc Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection
    T Louie
    University of Calgary, Calgary, Alberta, Canada
    Antimicrob Agents Chemother 53:223-8. 2009
    ....
  7. doi request reprint Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease
    B Guo
    Institute of Health Economics, Edmonton, Alberta, Canada
    Aliment Pharmacol Ther 35:865-75. 2012
    ..Management of recurrent Clostridium difficile-associated disease (CDAD), particularly in elderly patients, remains clinically challenging. Faecal transplantation (FT) may restore normal microbiota and break the cycle of recurrent CDAD...
  8. pmc Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada
    Duncan R MacCannell
    Department of Microbiology and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada
    J Clin Microbiol 44:2147-52. 2006
    ..PCR ribotype 027 strains appear to be widely distributed, to predate the Montreal outbreak, and to have measurable community presence in Western Canada...
  9. ncbi request reprint Treatment of first recurrences of Clostridium difficile-associated disease: waiting for new treatment options
    Thomas J Louie
    Clin Infect Dis 42:765-7. 2006
  10. ncbi request reprint Population-based epidemiological study of infections caused by carbapenem-resistant Pseudomonas aeruginosa in the Calgary Health Region: importance of metallo-beta-lactamase (MBL)-producing strains
    Kevin B Laupland
    Department of Medicine, University of Calgary, Centre for Anti microbial Resistance, and Calgary Health Region, Calgary, Alberta, Canada
    J Infect Dis 192:1606-12. 2005
    ....
  11. ncbi request reprint Population-based assessment of intensive care unit-acquired bloodstream infections in adults: Incidence, risk factors, and associated mortality rate
    Kevin B Laupland
    Division of Critical Care Medicine, University of Calgary, Calgary Health Region, Alberta, Canada
    Crit Care Med 30:2462-7. 2002
    ..The study objective was to define the incidence, risk factors, microbiology, and clinical outcomes of intensive care unit-acquired bloodstream infections...
  12. ncbi request reprint Incidence and risk factors for acquiring nosocomial urinary tract infection in the critically ill
    Kevin B Laupland
    Division of Critical Care Medicine, University of Calgary, Calgary Health Region, Canada
    J Crit Care 17:50-7. 2002
    ..However, the epidemiology of intensive care unit (ICU)-acquired UTIs is not well defined. The objective of this study was to describe the incidence, risk factors, and clinical outcomes of ICU-acquired UTIs...